174 related articles for article (PubMed ID: 8186141)
1. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group.
Arikian SR; Einarson TR; Kobelt-Nguyen G; Schubert F
Br J Dermatol; 1994 Apr; 130 Suppl 43():35-44. PubMed ID: 8186141
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.
Gupta AK
Pharmacoeconomics; 1998 Feb; 13(2):243-56. PubMed ID: 10178650
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
Casciano J; Amaya K; Doyle J; Arikian S; Shear N; Haspel M; Kahler K
Manag Care; 2003 Mar; 12(3):47-54. PubMed ID: 12685377
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model.
Marchetti A; Piech CT; McGhan WF; Neugut AI; Smith BT
Clin Ther; 1996; 18(4):757-77; discussion 702. PubMed ID: 8879902
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective.
Einarson TR; Arikian SR; Shear NH
Br J Dermatol; 1994 Apr; 130 Suppl 43():32-4. PubMed ID: 8186140
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
Gupta AK
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
[TBL] [Abstract][Full Text] [Related]
7. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis.
Gupta AK
J Am Podiatr Med Assoc; 2002 May; 92(5):272-86. PubMed ID: 12015408
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in Onychomycosis.
Jansen R; Redekop WK; Rutten FF
Pharmacoeconomics; 2001; 19(4):401-10. PubMed ID: 11383756
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.
Van Doorslaer EK; Tormans G; Gupta AK; Van Rossem K; Eggleston A; Dubois DJ; De Doncker P; Haneke E
Dermatology; 1996; 193(3):239-44. PubMed ID: 8944348
[TBL] [Abstract][Full Text] [Related]
10. A cost/efficacy analysis of oral antifungals indicated for the treatment of onychomycosis: griseofulvin, itraconazole, and terbinafine.
Angello JT; Voytovich RM; Jan SA
Am J Manag Care; 1997 Mar; 3(3):443-50. PubMed ID: 10173095
[TBL] [Abstract][Full Text] [Related]
11. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.
Baran R; Sigurgeirsson B; de Berker D; Kaufmann R; Lecha M; Faergemann J; Kerrouche N; Sidou F
Br J Dermatol; 2007 Jul; 157(1):149-57. PubMed ID: 17553051
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of two new treatments for onychomycosis: an analysis of two comparative clinical trials.
Bootman JL
J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S69-72. PubMed ID: 9594941
[TBL] [Abstract][Full Text] [Related]
13. [Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine].
Bergman W; Rutten FF
Ned Tijdschr Geneeskd; 1994 Nov; 138(47):2346-50. PubMed ID: 7969635
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
Gupta AK; Gregurek-Novak T
Dermatology; 2001; 202(3):235-8. PubMed ID: 11385230
[TBL] [Abstract][Full Text] [Related]
15. Terbinafine: a review of its use in onychomycosis in adults.
Darkes MJ; Scott LJ; Goa KL
Am J Clin Dermatol; 2003; 4(1):39-65. PubMed ID: 12477372
[TBL] [Abstract][Full Text] [Related]
16. A questionnaire study on the management of onychomycosis: a Canadian perspective.
Gupta AK; Shear NH
Int J Dermatol; 1998 Jun; 37(6):457-60. PubMed ID: 9646138
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA.
Gupta AK; Lambert J
Int J Dermatol; 1999 Sep; 38 Suppl 2():53-64. PubMed ID: 10515529
[No Abstract] [Full Text] [Related]
18. What is the cost of onychomycosis?
Sinclair R
Australas J Dermatol; 1998 May; 39(2):131-2. PubMed ID: 9611389
[No Abstract] [Full Text] [Related]
19. The new oral antifungal agents for onychomycosis of the toenails.
Gupta AK; Shear NH
J Eur Acad Dermatol Venereol; 1999 Jul; 13(1):1-13. PubMed ID: 10565624
[TBL] [Abstract][Full Text] [Related]
20. Fusarium onychomycosis: prevalence, clinical presentations, response to itraconazole and terbinafine pulse therapy, and 1-year follow-up in nine cases.
Ranawaka RR; Nagahawatte A; Gunasekara TA
Int J Dermatol; 2015 Nov; 54(11):1275-82. PubMed ID: 26223159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
